Dysregulation of aldosterone or cortisol production can predispose to hypertension, as seen in aldosteroneproducing adenoma, a form of primary aldosteronism. We investigated the role of microRNA (miRNA) in their production, with particular emphasis on the CYP11B1 (11β-hydroxylase) and CYP11B2 (aldosterone synthase) genes, which produce the enzymes responsible for the final stages of cortisol and aldosterone biosynthesis, respectively. Knockdown of Dicer1, a key enzyme in miRNA maturation, significantly altered CYP11B1 and CYP11B2 expression in a human adrenocortical cell line. Screening of nondiseased human adrenal and aldosterone-producing adenoma samples yielded reproducible but distinctive miRNA expression signatures for each tissue type, with levels of certain miRNA, including microRNA-24 (miR-24), differing significantly between the 2. Bioinformatic analysis identified putative binding sites for several miRNA, including miR-24, in the 3′ untranslated region of CYP11B1 and CYP11B2 mRNAs. In vitro manipulation of miR-24 confirmed its ability to modulate CYP11B1 and CYP11B2 expression, as well as cortisol and aldosterone production. This study demonstrates that Dicer-dependent miRNA, including miR-24, can post-transcriptionally regulate expression of the CYP11B1 and CYP11B2 genes. Normal adrenal tissue and aldosteroneproducing adenoma differ significantly and reproducibly in their miRNA expression profiles, with miR-24 significantly downregulated in the latter. Adrenal miRNA may, therefore, be a novel and valid target for the therapeutic manipulation of corticosteroid biosynthesis. (Hypertension. 2013;62:572-578.) • Online Data Supplement (J.M.C.). The online-only Data Supplement is available with this article at http://hyper.ahajournals.org/lookup/suppl/
T he corticosteroid hormones cortisol and aldosterone are important determinants of blood pressure and cardiovascular risk. Excess cortisol results in Cushing syndrome, associated with hypertension and accelerated atherogenesis, 1 whereas excess aldosterone, in primary aldosteronism, leads to severe hypertension with markedly increased risk of myocardial infarction, stroke, and left ventricular hypertrophy. 2 The frequency of primary aldosteronism in hypertensive patients is now accepted to be ≈5% to 10% 3, 4 ; recent studies show that aldosterone is an important predictor of cardiovascular risk and outcome, with levels toward the high end of the normal range predicting blood pressure and development of hypertension. 5 Controlled release of corticosteroids from the adrenal cortex is achieved, in part, by strictly regulated expression of genes encoding the steroidogenic enzymes that catalyze their biosynthetic pathways. The final enzymes in this process are particularly important: 11β-hydroxylase (CYP11B1) is responsible for the terminal conversion that produces cortisol, whereas aldosterone synthase (CYP11B2) fulfills the equivalent role in aldosterone production. The CYP11B1 and CYP11B2 genes lie in tandem on human chromosome 8 and have ≈93% sequence similarity within their coding regions. 6 Changes in the expression of these genes have been observed in cases of aldosterone-producing adenoma (APA). 7, 8 In addition, the rate of aldosterone production is known to be heritable, 9 and several polymorphisms in the CYP11B1 and CYP11B2 genes associate with altered 11β-hydroxylation, aldosterone production, or hypertension. 10 Although it is relatively straightforward to propose mechanisms by which polymorphisms in the 5′ regulatory regions of these genes, such as rs1799998, 11 could affect transcription, it is not immediately apparent how polymorphisms located in introns or the 3′ untranslated region (3′ UTR) of these genes could alter expression. However, in recent years, microR-NAs (miRNAs) have emerged as key regulatory molecules that regulate ≈30% of human genes. 12 They are endogenous, single-stranded noncoding RNA molecules of ≈22 nucleotides, produced through a series of maturation reactions mediated by the RNase III enzymes, Drosha and Dicer. 13 These post-transcriptional regulatory molecules exert their effects by targeting the 3′ UTR of specific mRNAs. Through mRNA destabilization or transcriptional repression, miRNAs act not as simple on-off switches for expression but rather as fine-tuning modulators of mRNA levels. Differential binding of miRNAs, based on abundance or target sequence variation, might account for altered gene expression and, therefore, protein synthesis.
The influence of miRNAs has been seen in cancer, cardiovascular disease, developmental processes, and tumorogenesis. However, few studies have investigated their impact on the regulation of corticosteroid production, and their role in adrenal gland pathophysiology remains poorly understood. Targeted deletion of Dicer elicits effects on adrenal cell development and survival, 14 and miRNAs are also known to be dysregulated in adrenal carcinomas. 15 Although the regulation of aldosterone production by miR-21 has been demonstrated, no direct effect on specific target mRNAs was shown. 16 Here, we investigate the post-transcriptional effects of miR-NAs on CYP11B2 and CYP11B1 expression and on corticosteroid production in the human adrenal cortex. Through short inhibitory RNA (siRNA) knockdown of Dicer expression in a human adrenocortical cell line, we demonstrate that CYP11B1 and CYP11B2 mRNAs are subject to Dicer-mediated miRNA regulation. We also use bioinformatic analysis to identify putative miRNA target sites located in the 3′ UTR of CYP11B1 and CYP11B2 mRNAs and determine whether miRNAs predicted to bind to these sites are expressed in nondiseased adrenal tissue. We then identify miRNAs that are differentially expressed in adrenal tissue from patients with constitutive production of aldosterone as a result of APA, demonstrating reproducible differential expression of specific miRNAs between these tissue types. Finally, we show that one such miRNA, microRNA-24 (miR-24), is able to target both CYP11B1 and CYP11B2 mRNAs directly, significantly decreasing aldosterone and cortisol production in adrenocortical cells.
Methods
For full Materials and Methods, see the online-only Data Supplement.
H295R Cells
These were a gift from Prof William Rainey (Medical College of Georgia, Augusta, GA). 17
Human Tissue Samples
Four frozen nondiseased adrenal tissue samples were obtained from white adult patients undergoing nephrectomy, with full local ethical approval from the University of Birmingham, United Kingdom. The analyzed tissue was predominantly cortical. Four samples of formalin-fixed paraffin-embedded APA tissue were obtained from the University of Glasgow Biobank. Use of tissue in this study was conducted in accordance with the requirements of the Human Tissue Act and with appropriate permission from the local ethical review board. Participants provided informed consent.
Data Analysis
Real-time quantitative reverse transcriptase polymerase chain reaction results were analyzed using the relative quantification method of comparative C t (ΔΔC t ). 18 In vitro results were analyzed using either an unpaired Student t test or 1-sample t test, as stated. Analysis of results for multiple groups was performed by 1-way ANOVA and Bonferroni post hoc test, comparing all results to a designated control group or to all sets of data, as required. Microarray signal intensities were compared between tissue groups using a 2-way ANOVA and Bonferroni post hoc test. Statistical analysis was performed using GraphPad 
Results siRNA Knockdown of Dicer1
Two prevalidated Dicer1-targeted siRNA molecules, Dicer1A and Dicer1B (Applied Biosystems), were separately transfected into the H295R adrenocortical cell line. Real-time reverse transcriptase polymerase chain reaction analysis of RNA isolated 48 hours post-transfection showed that each siRNA significantly reduced the level of Dicer1 mRNA relative to a scrambled negative control siRNA ( Figure 1A ). Dicer1A inhibition of Dicer1 significantly increased CYP11B1 and CYP11B2 mRNAs relative to scrambled negative control RNA, although a statistically significant effect was not observed with Dicer1B siRNA ( Figure 1B and 1C ). Table S1 in the online-only Data Supplement). The number of unique miRNAs predicted by ≥1 algorithm to have a target site within the 3′ UTR totaled 202 for CYP11B1 and 172 for CYP11B2. Bioinformatic analysis of the entire human CYP11B1 and CYP11B2 genes, including introns and the intragenic region, did not identify any sequence known to produce existing miRNAs (miRBase v.18).
Bioinformatic Prediction of miRNA-Binding Sites in CYP11B1 and CYP11B2 3′ UTRs
miRNA Profiling of APA and Nontumorous Adrenal Tissue miRNA expression was assessed by µParaflo technology microarray analysis (v.10.1, LC Sciences, Houston, TX) in total RNA isolated from 4 nondiseased adrenal tissue samples and 4 APA tissue samples. One hundred and three miR-NAs were present in nontumorous tissue above the stated threshold level (500 arbitrary units) and 62 in APA samples. Microarray results for individual miRNAs within each tissue group were highly consistent across each of the 4 samples, whereas signals for individual miRNAs were also highly correlated between nontumorous tissue and APA (P<0.0001; r 2 , 0.821; Figure 2A ). We combined these microarray data, indicating the presence of miRNAs, with the previous bioinformatic analysis predicting possible miRNA-binding sites in the CYP11B1 and CYP11B2 3′ UTRs, thereby enabling us to identify those miRNAs that could plausibly have a direct post-transcriptional role in CYP11B1 and CYP11B2 regulation. Seven such miRNAs were each predicted to bind both the CYP11B1 and the CYP11B2 3′ UTRs, of which 3 (miR-10b, miR-24, and miR-34c-3p) were present at significantly different levels in nontumorous adrenal and APA tissue ( Figure 2B ). Of these, only miR-10b and miR-24 were expressed above the threshold level in both tissue types. These 2 miRNAs were, therefore, selected for further investigation.
miR-24 Effects on CYP11B1, CYP11B2, and Steroid Production
The effects of miR-10b and miR-24 on the regulation of CYP11B1 and CYP11B2 were assessed by transfecting H295R cells with pre-miR molecules, which artificially supplement the endogenous levels of specific miRNAs. Real-time reverse transcriptase polymerase chain reaction analysis conducted using RNA isolated 48 hours post-transfection showed that miR-10b pre-miRs caused no significant change in CYP11B1 or CYP11B2 mRNA levels relative to a scrambled negative control miRNA (data not shown); therefore, miR-10b was not subjected to any further investigation. However, relative to scrambled negative control RNAs, transfection with miR-24 pre-miR significantly reduced CYP11B1 mRNA 0.64±0.06-fold (P=0.037; Figure 3A ) and CYP11B2 mRNA 0.58±0.07-fold (P=0.026; Figure 3B ). Cells were then transfected with the miR-24 anti-miR, which, by competitive binding of endogenous miR-24, specifically reduces its availability. Anti-miR had the opposite effect to pre-miR, increasing the abundance of CYP11B1 mRNA 1.38±0.05-fold (P=0.02; Figure 3A ) and CYP11B2 mRNA 1.32±0.06-fold (P=0.035; Figure 3B ) relative to control. These results are consistent with canonical regulation of CYP11B1 and CYP11B2 by miR-24 in H295R cells. Real-time reverse transcriptase polymerase chain reaction measurement of miR-24 confirmed the respective increase and decrease in its levels as a result of pre-miR and anti-miR transfection (both P<0.001; Figure 3C and 3D). Furthermore, we observed significant alterations in steroid production rates (as measured by liquid chromatography tandem mass spectrometry), 19 which correlated with changes in CYP11B1 and CYP11B2 mRNA abundance.
As CYP11B2 mRNA level fell, so too did aldosterone levels within the cell media, declining significantly 0.78±0.02-fold Figure 3E ). Similarly, cortisol production fell in response to the pre-miR (0.71±0.05-fold; P=0.033), although a corresponding significant increase in response to anti-miR was not observed (0.93±0.03-fold; P=0.144; Figure 3F ).
Target Validation of miR-24 by Reporter Constructs
Reporter construct studies investigated whether miR-24 effects could be attributed to direct targeting of the CYP11B1 and CYP11B2 mRNA 3′ UTRs, as predicted by bioinformatic analysis (Figure 4A ). Expression vectors fusing the coding region of the firefly luciferase gene to the 3′ UTR of CYP11B1 (pEZX-B1) or CYP11B2 (pEZX-B2) were constructed. Each construct also contained a renilla luciferase gene fused to a separate constitutive promoter, which provided an index of transfection efficiency. A single nucleotide in each of the bioinformatically predicted miR-24 seed sites within these constructs was then mutated, as illustrated in Figure 4A ; for pEZX-B1 constructs, where 2 miR-24 sites were predicted, singly mutated constructs were prepared, as well as a construct containing mutations at both sites (combined). A noinsert vector (pEZX-C) acted as control. Luciferase activity was found to be significantly increased in cells transfected with pEZX-B1 mutated at either of the predicted miR-24 sites, relative to the original nonmutated pEZX-B1 construct Figure 4B ). Furthermore, the pEZX-B1 construct mutated at both sites gave a higher luciferase activity than either of the singly mutated constructs, as well as the nonmutated pEZX-B1 ( Figure 4B ). Relative luciferase activities were not different between the mutated and nonmutated pEZX-B2 plasmids ( Figure 4C ).
Each nonmutated construct was then cotransfected into HeLa cells alongside miR-24 pre-miR, but the resulting luciferase activity was not found to be different from that produced by cotransfection with a scrambled pre-miR sequence (data not shown). However, cotransfection with miR-24 anti-miR significantly increased luciferase activity of the nonmutated CYP11B1 (137.30±5.87%; P=0.023; Figure 4D ) and CYP11B2 (162.80±11.20%; P=0.030; Figure 4E ) constructs in HeLa cells, compared with cells transfected with a scrambled anti-miR. Mutation of either of the predicted miR-24 seed sites in the 3′ UTR of CYP11B1 attenuated this anti-miR effect on luciferase activity, whereas mutation of both sites reduced the luciferase activity level to that of the control ( Figure 4D) . Similarly, mutation of the predicted miR-24 seed site in pEZX-B2 abolished the increased activity that anti-miR elicited in the nonmutant plasmid construct ( Figure 4E ).
Discussion
Our disruption of miRNA production in an adrenocortical cell line by silencing of Dicer1 used 2 different siRNAs, each of which reduced Dicer1 mRNA levels by ≈0.5-fold after 48 hours. This fairly modest reduction in transcript levels possibly reflects the relative difficulty of transfecting H295R cells. Dicer1A siRNA resulted in significantly increased CYP11B1 and CYP11B2 mRNA levels, whereas Dicer1B did not, presumably because of a greater silencing effect by Dicer1A.
Nevertheless, the derepression of CYP11B1 and CYP11B2 on miRNA depletion confirms that these genes are subject to endogenous negative regulation by miRNAs.
As our bioinformatic analysis indicates that no miRNAs originate from the CYP11B1/CYP11B2 locus, we focused on identifying sites at which miRNAs might act. Putative miRNA target sites located in the 3′ UTR of CYP11B1 and CYP11B2 mRNAs were predicted using 4 different bioinformatic algorithms and resulted in highly variable results from each (Table S1 ). We pooled these data to improve accuracy and minimize the risk of falsely excluding certain sites. A large number of predicted binding sites were common to CYP11B1 and CYP11B2, presumably because of the 3′ UTR sequence similarity of the 2 genes (≈80%), which is comparable with that of transcription factor-binding sites in their 5′ regulatory regions. 20, 21 Nevertheless, numerous miRNAs are predicted to bind only 1 of the 2 transcripts, so the potential exists for independent, as well as common, miRNA-mediated regulation of these genes.
The number and quantity of miRNAs detected in adrenal tissue were remarkably consistent. Other studies analyzing adrenal miRNAs have been published, 15, [22] [23] [24] [25] but comparison is difficult as a result of the various profiling platforms used and the incomplete presentation of data; only Soon et al 15 used a microarray system with a level of miRNA coverage equal to that used here (ie, 100% of the miRNAs in miRBase v.10). Our results from APA tissue were also highly consistent, and levels of many miRNAs correlated with those in nondiseased adrenal tissue. However, several miRNAs present in APA were either absent or present at significantly different levels from those in normal tissue. Therefore, APAs have an miRNA profile distinct from that of nontumorous adrenal tissue. Seven miRNAs predicted to bind both CYP11B1 and CYP11B2 mRNAs were present in both normal and APA tissue: miR-10b, miR-140-3p, miR-143, miR-24, miR-22, miR-34a, and miR-34c-3p. Three were present at significantly different levels in APA and normal tissue, and, of these, miR-10b and miR-24 were expressed above threshold levels in both APA and nontumorous tissue. Although these were selected for target validation studies, there are likely to be further miR-NAs that regulate corticosteroidogenesis.
Target validation confirmed that miR-24, but not miR-10b, regulates CYP11B1 and CYP11B2 mRNA abundance and steroid production. Although reporter construct studies found that reduction in miR-24 levels increases the activity of luciferase genes fused to CYP11B1 and CYP11B2 3′ UTRs, a corresponding decrease after overexpression of miR-24 was not observed. One possible explanation for this is that high endogenous levels of miR-24 in HeLa cells may already saturate available miR-24 target sites and repress the construct at a maximal level. 26 Nevertheless, experiments with anti-miRs provided further confirmation that miR-24 regulation of CYP11B1 and CYP11B2 occurs via mRNA 3′ UTR sequence. Results from H295R cells are consistent with miR-24 acting to regulate both of these genes in a canonical miRNA manner. Furthermore, our mutagenesis studies confirm that miR-24 represses CYP11B1 and CYP11B2 via the bioinformatically predicted sites. The complete abolition of miR-24 effects relative to controls suggests that no further miR-24 sites are present in the CYP11B1 and CYP11B2 transcripts and that all functional miR-24 sites at these loci were predicted by our in silico analysis. Our results also show that both sites in the CYP11B1 3′ UTR are functional and seem to mediate repression by miR-24 to a similar degree.
This study indicates that miR-24 targets a single sequence common to the CYP11B1 and CYP11B2 genes: an offset 6-mer site with an additional G:U wobble pairing at base 2, which can be tolerated in miRNA seed sites ( Figure 4A) . 27 There is a further miR-24 target site unique to the CYP11B1 3′ UTR; this 7-mer-m8 site does have a mismatch in the seed region, but the large degree of base-pairing complementarity within the center region and 3′ end of the miRNA most likely compensate for this. 28 miR-24 is transcribed from 2 different genomic locations, each as part of a triplet cluster: miR-24-2 is grouped with miR-23a and miR-27a in an intergenic region on chromosome 19, whereas miR-24-1, miR-23b, and miR-27b cluster in an intron on chromosome 9 ( Figure S1 ). As the 2 miR-24s have identical mature sequences but different primary transcripts, they will share biological function but may have different expression patterns. 29 Our data show that miR-23b and miR-27b are also downregulated in APA, in agreement with the observed reduction in miR-24 ( Figure S1B ). We tested other members of the miR-24-1 cluster for effects on CYP11B1 and CYP11B2 (miR-23b has a putative binding site on CYP11B1), but neither yielded results consistent with canonical miRNA action (data not shown).
The genomic locus spanning the miR-24-1 cluster, C9orf3, encodes a novel metalloprotease called aminopeptidase-O. 30 A closely related enzyme, aminopeptidase-A, plays a crucial role in blood pressure regulation and is integral to the renin-angiotensin system, cleaving angiotensin II to angiotensin III. 31, 32 Although the role of aminopeptidase-O is less well defined, it can cleave angiotensin III to angiotensin IV. 30 Angiotensin III, but not angiotensin IV, stimulates aldosterone production in the adrenal gland by a mechanism thought to involve type 2 angiotensin II receptors. 33 Reduced transcription at this locus in APA could, therefore, stimulate aldosterone production via post-transcriptional CYP11B2 regulation while simultaneously reducing angiotensin III cleavage. Further investigation of aminopeptidase-O and of the miR-NAs transcribed within its introns will be of interest.
A regulatory role for miR-24 has been identified in several other cellular pathways, and its action often seems to be cell-type specific, contributing to opposing cell mechanisms, such as cell proliferation and cell apoptosis, depending on context. 34, 35 The majority of validated targets for miR-24 are related to regulation of the cell cycle, 29 which may explain its observed differential expression in tumor tissue; whether miR-24 contributes to adrenal plasticity remains to be determined.
Perspectives
We have shown that Dicer-mediated miRNAs in adrenocortical tissue regulate corticosteroid production. Generation of miRNA profiles from nontumorous adrenal tissue, in combination with bioinformatic analysis, enabled us to identify those miRNAs most likely to regulate the terminal stages of aldosterone and cortisol biosynthesis through repression of CYP11B1 and CYP11B2 mRNA function. Comparison of these with APA profiles highlighted miRNAs likely to be involved in the dysregulation of corticosteroidogenesis and to contribute to tumorigenesis. In this way, we identified miR-24 as a probable repressor of these transcripts and confirmed this through in vitro experiments, which also demonstrated significant changes in steroid production. Future research will focus on the identification and validation of further miRNA species likely to act on CYP11B1, CYP11B2, and the various other components of this pathway. We expect such work to reveal a complex regulatory network capable of modulating steroid production with a fine degree of control, which may also provide insights into the development of functional adrenal tumors.
Supplemental Methods
Cell Culture -The H295R human adrenocortical tumour cell line (a gift from Prof. William Rainey, Medical College of Georgia, U.S.A.) 17 was maintained in Dulbecco's modified Eagles medium/F12 (1:1) with HEPES buffer (Invitrogen). This was supplemented with 2.5% Ultroser G (Pall Bioscience), 1% Insulin-transferrinselenium (ITS) (BD Biosciences), 1IU penicillin, 100µg/mL streptomycin (Invitrogen). HeLa cells (European Collection of Animal Cell Cultures) were maintained in Dulbecco's modified Eagles medium supplemented with 10% (v/v) fetal calf serum (FCS), 2mM L-glutamine, 1IU penicillin and 100µg/ml streptomycin (Invitrogen).
Human Tissue Samples -Four frozen non-diseased adrenal tissue samples were obtained from white adult patients undergoing nephrectomy, with full local ethical approval from the University of Birmingham, UK. The analysed tissue was predominantly cortical. Four samples of formalin-fixed paraffin-embedded (FFPE) APA tissue was obtained from the University of Glasgow Biobank. Use of tissue in this study was conducted in accordance with the requirements of the Human Tissue Act and with appropriate permission from the local ethical review board. Participants gave informed consent.
RNA Isolation -Total RNA, including the miRNA fraction, was isolated from H295R cells grown in 6-well plates and from frozen tissue samples using the miRNeasy mini kit (QIAGEN), according to the manufacturer's instructions. Cells were directly lysed using 700µl of QIAzol per well, or else 40mg of frozen tissue was lysed in a FastPrep Lysing Matrix D Tube with 700µl of QIAzol. Total RNA was isolated from four 20µm FFPE tissue sections using the RecoverAll™ Total Nucleic Acid Isolation Kit (Applied Biosystems) according to the manufacturer's instructions. RNA concentration was determined by Nano-Drop® and its quality assessed using the Bioanalyser 2100 apparatus (Agilent).
miRNA Microarray Analysis -miRNA microarray analyses were performed by LC Sciences (Houston, Texas, U.S.A.), using 5µg of the total RNA. Samples were quality checked prior to proceeding with the miRNA µParaflo ® technology microarray (version 10.1), then labelled with a fluorescent dye and hybridised overnight to a microfluidic chip containing complementary probes for 723 human miRNAs and other RNA controls. Post-array analysis utilised internal spike-in controls to crossnormalise the array data output, allowing signals to be compared between chips.
Cell Transfection -H295R Cells were transfected using siPORT NeoFX Transfection Agent (Ambion), according to manufacturer's instructions. They were transfected with Pre-miR™ or Anti-miR™ molecules (Applied Biosystems) to a final concentration of 50nM, or with pre-validated siRNA molecules (Dicer 1A: Product no. s23755; Dicer 1B: s23756, Applied Biosystems) to a final concentration of 30nM, in 6-well plates at a final cell density of 4.8x10 5 cells/well. HeLa cells were cotransfected with pEZX-construct (500ng) and either Pre-miR™ or Anti-miR™ in 24well plates at a final cell density of 8×10 4 cells/well.
Real-Time Quantitative Reverse Transcriptase PCR (qRT-PCR)
-First-strand cDNA was generated in a 20µl volume using the miScript RT Kit (QIAGEN) and 200ng of total RNA. The resulting cDNA was diluted to a final volume of 100µL and 2µl of this Supplemental Table   Table S1 : Bioinformatic analysis identifying putative miRNA-binding sites in the human CYP11B1 and CYP11B2 3'UTRs. The total number of miRNA binding sites identified by each database within the relevant 3'UTR is shown, with the number of different miRNAs predicted to bind that 3'UTR in parentheses. The right-hand column shows the total number of different miRNAs predicted, by at least one database, to bind that 3'UTR. 
